-
1.发明授权COMBINATION THERAPY WITH GLATIRAMER ACETATE AND MITOXANTRONE FOR THE TREATMENT OF MULTIPLE SCLEROSIS 有权随着对治疗多发性硬化症的醋酸格拉替雷和米托蒽醌联合治疗
公开(公告)号：EP1638589B1
公开(公告)日：2014-03-26
申请号：EP04752284.2
申请日：2004-05-14
发明人： VOLLMER, Timothy
IPC分类号： A61K38/02 , A61K31/137 , A61P25/28
CPC分类号： A61K31/137 , A61K38/02 , A61K2300/00
-
2.发明公开NEW STABLE FORMULATIONS OF RECOMBINANT HUMAN ALBUMIN-HUMAN GRANULOCYTE COLONY STIMULATING FACTOR FUSION PROTEIN 审中-公开重组人白蛋白人粒细胞集落刺激因子的融合蛋白的新的稳定的制剂
公开(公告)号：EP2387420A2
公开(公告)日：2011-11-23
申请号：EP10701082.9
申请日：2010-01-15
CPC分类号： A61K38/385 , A61K38/193 , A61K38/38 , A61K47/643
摘要： Disclosed are compositions and methods for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count. The methods and compositions described herein include a fusion polypeptide formed from human serum albumin protein ("HSA") and human granulocyte- colony stimulating factor ("G-CSF").
-
3.发明授权STABLE PHARMACEUTICAL COMPOSITIONS OF 2-AZA-BICYCLO¬3.3.0 -OCTANE-3-CARBOXYLIC ACID DERIVATIVES 有权作者2-氮杂 - 辛烷BICYCLO¬3.3.0-3-羧酸衍生物的稳定的药物组合物
公开(公告)号：EP1635792B1
公开(公告)日：2009-03-04
申请号：EP04756130.3
申请日：2004-06-24
IPC分类号： A61K9/26 , A61K9/16 , A61K31/403
CPC分类号： A61K31/40 , A61K9/145 , A61K9/1617 , A61K9/2009 , A61K9/2054 , A61K31/403 , A61K47/14
摘要： A stable composition of a 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivative and a method for its preparation are described. The stable composition includes an intimate admixture of the derivative and a stabilizing effective amount of a lubricant. The stable composition further includes an external excipient. A method of preparing the stable composition includes forming an intimate admixture of the derivative and a lubricant and then blending the intimate admixture with at least one excipient. Preferably the final blend is transformed into solid unit dosage form.
-
公开(公告)号：EP1810676B1
公开(公告)日：2008-11-12
申请号：EP06251210.8
申请日：2006-03-07
发明人： Hrakovsky, Julia
IPC分类号： A61K31/4015
CPC分类号： A61K31/40 , A61K9/1652 , A61K9/2054 , A61K9/2059
-
5.发明公开CRYSTAL FORMS OF (S)-(+)-N,N-DIMETHYL-3-(1-NAPHTHALENYLOXY)-3-(2-THIENYL) PROPANAMINE OXALATE AND THE PREPARATION THEREOF 审中-公开（+） - - N，N-二甲基-3-（1-萘氧基）-3-（2-噻吩基）丙胺草酸盐和它们的制备（S）CRYSTAL FORMS
公开(公告)号：EP1856087A1
公开(公告)日：2007-11-21
申请号：EP06737570.9
申请日：2006-03-08
发明人： INI, Santiago , LIBERMAN, Anita , KOLTAI, Tamas
IPC分类号： C07D333/20
CPC分类号： C07D333/20
摘要： DNT-Oxal crystalline forms and processes for making DNT-Oxal crystalline forms are provided. DNT-Oxal refering to the compound (S) -(+) -N, N -dimethyl -3-(1- naphlthalenyloxy)-3-(2-thienyl) -propanamine oxalate .
-
6.发明公开IMPROVED PROCESS FOR THE SYNTHESIS OF ENANTIOMERIC INDANYLAMINE DERIVATIVES 审中-公开VERBESSERTES VERFAHREN ZUR SYNTHESE ENANTIMERISCHER INDANYLAMIN-DERIVATE
公开(公告)号：EP1851188A1
公开(公告)日：2007-11-07
申请号：EP06765604.1
申请日：2006-02-20
IPC分类号： C07C209/16 , C07C269/06 , C07C271/44 , C07C29/143 , C07C29/145
CPC分类号： C07C269/06 , C07B2200/07 , C07C29/143 , C07C209/16 , C07C2602/08 , C07C211/42 , C07C271/44 , C07C35/32
摘要： A process for manufacturing (R)-propynylaminoindans, and alternatively, a process for manufacturing (S)- propynylaminoindans. The chiral propynylaminoindans include alkoxy or alkylcarbamates derivatives. The process comprises transfer or pressure hydrogenation in the presence of an optically active catalyst to reduce 1-indanones. The chiral product, either (S)- or (R)- indanols undergo nucleophilic substitution to produce the named product. In an additional aspect, the invention relates to novel intermediates and compounds, namely, substituted indanones, substituted (S)- indanols and substituted (R)- indanols.
摘要翻译： 制备（R） - 丙炔基氨基茚满的方法，或者，制备（S） - 丙炔基氨基茚满的方法。 手性丙炔基氨基甘氨酸包括烷氧基或烷基氨基甲酸酯衍生物。 该方法包括在光学活性催化剂的存在下转移或加压氢化以还原1-茚满酮。 （S） - 或（R） - 茚满醇的手性产物经历亲核取代产生命名的产物。 在另一方面，本发明涉及新的中间体和化合物，即取代的茚满酮，取代的（S） - 茚满醇和取代的（R） - 茚满醇。
-
公开(公告)号：EP1746975A2
公开(公告)日：2007-01-31
申请号：EP05767572.0
申请日：2005-04-01
IPC分类号： A61K9/00
CPC分类号： A61K9/1611 , A61K9/1617 , A61K9/1676 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K31/52 , A61K31/522
摘要： The present invention provides enteric ally coated formulations of 6-mercaptopurine that exhibit a delay in release of the 6-mercaptopurine such that substantial release of 6-mercaptopurine does not occur until after passage through the stomach. Optionally, the formulations also comprise a delay coating in addition to the enteric coating that provides an even further delay such that substantial release of 6-mercaptopurine does not occur until after a certain period of time following passage through the stomach. Such a period of time is preferably at least one hour after passage through the stomach. Following the delay imparted by the enteric coating and optional delay coating, the formulations exhibit better bioavailability and faster dissolution than previous formulations.
-
8.发明公开SUSTAINED RELEASE FORMULATION OF N-(2-PROPYLPENTANOYL) GLYCINAMIDE AND RELATED COMPOUNDS 审中-公开N-（2-丙基戊）的表达甘氨酰胺持续释放和相关链接
公开(公告)号：EP1626707A2
公开(公告)日：2006-02-22
申请号：EP04708594.9
申请日：2004-02-05
发明人： LICHT, Daniella , LOVINGER, Ioana , ABD-ELHAI, Suher , DAGAN-LION, Mazzi , GILBERT, Adrian , LEIBOVITCH, Noa , COHEN, Sasson , LEVY, Ruth
IPC分类号： A61K9/20
CPC分类号： A61K31/16 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2054 , A61K31/19
摘要： The subject provides a sustained release tablet comprising the following components: a) a uniform admixture of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure of formula (I) or formula (II), wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and a binder, and b) a hydroxypropylmethyl cellulose, a process for manufacturing the tablet and a method of treating neuropathic pain, epilepsy, mania in bipolar disorder, a headache disorder, pain or of effecting pain prophylaxis in a subject.
-
9.发明公开PROCESS FOR PREPARING 2-(PYRIDINYL)METHYL SULFINYL-SUBSTITUTED BENZIMIDAZOLES AND NOVEL CHLORINATED DERIVATIVES OF PANTOPRAZOLE 审中-公开用于生产（吡啶基）甲基亚磺酰基的苯并咪唑取代的和泮托拉唑的新氯化衍生物
公开(公告)号：EP1615913A2
公开(公告)日：2006-01-18
申请号：EP04755278.1
申请日：2004-06-10
发明人： LIBERMAN, Anita , SINGER, Claude , RAIZI, Yuriy , PILARSKY; Gideon , BRAUDE, Viviana , FINKELSTEIN, Nina , CHEN, Kobi
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： The present invention provides a process comprising admixing a thioether with about 1.05 to about 1.6 molar equivalents of an active chlorine-containing oxidant, preferably sodium hypochlorite, and about 2.5 to about 5.0 molar equivalents of an alkali metal base; and recovering a sulfoxide that is preferably pantoprazole, lansoprazole, omeprazole, or rabeprazole. The process may further comprise contacting the sulfoxide with a source of sodium ions, preferably sodium hydroxide, to produce the sodium salt of the sulfoxide. The invention also relates to novel chlorinated derivatives of pantoprazole including 5(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-chloromethyl]sulfinyl]-1H- benzimidazole and 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)chlorohydroxymethyl] sulfinyl]-1H-benzimidazole and processes for making them. The invention also relates to processes of quantifying and identifying a compound other than pantoprazole in a mixture of pantoprazole and at least one other compound.
-
10.发明公开
公开(公告)号：EP1567124A1
公开(公告)日：2005-08-31
申请号：EP03781729.3
申请日：2003-11-03
IPC分类号： A61K9/00 , A61K31/4168 , A61K31/4178 , A61K31/433
CPC分类号： A61K9/0056 , A61K9/2018 , A61K9/2054 , A61K9/2072 , A61K9/2826 , A61K9/2866 , A61K31/4168 , A61K31/4178 , A61K31/433
摘要： Sublingual and buccal administration of the muscle spasm suppressor tizanidine increase its bioavailability by avoiding first-pass metabolism in the liver and reduce the inter-patient variation in bioavailability.
-
-
-
-
-
-
-
-
-
搜索结果
114 条记录 (耗时 0.041 秒)
